Valion Bio, Inc.
VBIO
$2.40
-$0.11-4.20%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | 146.00K | 86.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | 146.00K | 86.00K |
| Cost of Revenue | -- | -- | -- | 291.00K | -- |
| Gross Profit | -- | -- | -- | -145.00K | -- |
| SG&A Expenses | 3.72M | 3.78M | 1.22M | 1.48M | 1.02M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.42M | 5.63M | 2.21M | 2.63M | 1.68M |
| Operating Income | -6.42M | -5.63M | -2.36M | -2.48M | -1.68M |
| Income Before Tax | -7.06M | -6.23M | -2.35M | -2.60M | -1.68M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -7.06M | -6.23M | -2.35M | -2.60M | -1.68M |
| Earnings from Discontinued Operations | -46.00K | 23.00K | -500.00K | -- | -256.00K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.10M | -6.20M | -2.85M | -2.60M | -1.93M |
| EBIT | -6.42M | -5.63M | -2.36M | -2.48M | -1.68M |
| EBITDA | -6.07M | -5.63M | -2.36M | -2.48M | -1.68M |
| EPS Basic | -54.36 | -55.81 | -29.33 | -50.01 | -54.81 |
| Normalized Basic EPS | -32.62 | -33.73 | -15.56 | -29.33 | -29.70 |
| EPS Diluted | -54.36 | -55.81 | -29.33 | -50.01 | -54.81 |
| Normalized Diluted EPS | -32.62 | -33.73 | -15.56 | -29.33 | -29.70 |
| Average Basic Shares Outstanding | 135.20K | 115.30K | 46.20K | 52.80K | 35.30K |
| Average Diluted Shares Outstanding | 135.20K | 115.30K | 46.20K | 52.80K | 35.30K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |